MAIA Biotechnology, Inc.

For the period ended Dec 31, 2025. Filed Mar 23, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 23, 2026

MAIA$1.09+2.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31, 2025	December 31, 2024
ASSETS
Current assets:
Cash	$8,658,031	$9,601,298
Prepaid expenses and other current assets	1,043,825	473,834
Australia research and development incentives receivable	—	77,347
Total current assets	9,701,856	10,152,479
Other assets	2,800	2,800
Total assets	$9,704,656	$10,155,279
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$2,038,803	$1,512,436
Accrued expenses	3,797,595	2,317,602
Total current liabilities	5,836,398	3,830,038
Long term liabilities:
Warrant liability	1,492,395	2,690,605
Total liabilities	7,328,793	6,520,643
Commitments and contingencies (Note 7)	-	-
Stockholders’ equity (deficit)
Preferred stock, 0.0001 par value, 30,000,000 shares authorized at December 31, 2025 and December 31, 2024, 0 shares issued and outstanding	—	—
Common stock, $0.0001 par value, 150,000,000 and 70,000,000 shares authorized at December 31, 2025 and December 31, 2024, 38,624,289 and 26,157,788 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	3,863	2,616
Additional paid-in capital	112,053,233	90,897,468
Accumulated deficit	(109,631,005)	(87,234,833)
Accumulated other comprehensive loss	(50,228)	(30,615)
Total stockholders’ equity	2,375,863	3,634,636
Total liabilities and stockholders’ equity	$9,704,656	$10,155,279

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.